Literature DB >> 20007142

Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study.

Anja B U Mäkelburg1, Nic J G M Veeger, Saskia Middeldorp, Karly Hamulyák, Martin H Prins, Harry R Büller, Willem M Lijfering.   

Abstract

The term factor V Leiden (FVL) paradox is used to describe the different risk of deep vein thrombosis and pulmonary embolism that has been found in carriers of FVL. In a thrombophilic family-cohort, we estimated differences in absolute risks of deep vein thrombosis and pulmonary embolism for various thrombophilic defects. Of 2,054 relatives, 1,131 were female, 41 had pulmonary embolism and 126 deep vein thrombosis. Annual incidence for deep vein thrombosis in non-carriers of FVL was 0.19% (95%CI, 0.16-0.23), and 0.41% (95%CI, 0.28-0.58) in carriers; relative risk (RR) 2.1 (95%CI, 1.4-3.2). For pulmonary embolism these incidences were similar in carriers and non-carriers 0.07%, respectively; RR 1.0 (95% CI, 0.4-2.5). When co-inheritance of other thrombophilic defects was excluded the RR for deep vein thrombosis in FVL carriers was 7.0 (95%CI, 2.3-21.7) compared to non-carriers and 2.8 (95%CI, 0.5-14.4) for pulmonary embolism. For other thrombophilic defects no such effect was observed. Thus the FVL paradox was confirmed in our study. However, a similar paradox in carriers of other thrombophilic defects was not observed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007142      PMCID: PMC2878805          DOI: 10.3324/haematol.2009.017061

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism.

Authors:  H Bounameaux
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

2.  The prevalence of risk factors for venous thromboembolism among hospital patients.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; A Forcier
Journal:  Arch Intern Med       Date:  1992-08

3.  Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis.

Authors:  G Meyer; J Emmerich; D Helley; E Arnaud; V Nicaud; M Alhenc-Gelas; M Aiach; A Fischer; H Sors; J N Fiessinger
Journal:  Am J Med       Date:  2001-01       Impact factor: 4.965

4.  Coagulation factor V Leiden mutation in sudden fatal pulmonary embolism and in a general northern European population sample.

Authors:  K Kuismanen; M L Savontaus; A Kozlov; A F Vuorio; A Sajantila
Journal:  Forensic Sci Int       Date:  1999-12-06       Impact factor: 2.395

5.  Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.

Authors:  J Emmerich; F R Rosendaal; M Cattaneo; M Margaglione; V De Stefano; T Cumming; V Arruda; A Hillarp; J L Reny
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

6.  Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study.

Authors:  Ivan Bank; Eduard J Libourel; Saskia Middeldorp; Elisabeth C M Van Pampus; Maria M W Koopman; Karly Hamulyák; Martin H Prins; Jan Van Der Meer; Harry R Büller
Journal:  Arch Intern Med       Date:  2004-09-27

7.  The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects.

Authors:  Willem M Lijfering; Michiel Coppens; Marlène H W van de Poel; Saskia Middeldorp; Karly Hamulyák; Ivan Bank; Nic J G M Veeger; Martin H Prins; Harry R Büller; Jan van der Meer
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

8.  Mechanisms of the factor V Leiden paradox.

Authors:  K J van Stralen; C J M Doggen; I D Bezemer; E R Pomp; T Lisman; F R Rosendaal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

9.  Incidence and mortality of venous thrombosis: a population-based study.

Authors:  I A Naess; S C Christiansen; P Romundstad; S C Cannegieter; F R Rosendaal; J Hammerstrøm
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

10.  A prospective study of the incidence of deep-vein thrombosis within a defined urban population.

Authors:  M Nordström; B Lindblad; D Bergqvist; T Kjellström
Journal:  J Intern Med       Date:  1992-08       Impact factor: 8.989

View more
  5 in total

Review 1.  Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox.

Authors:  Javier Corral; Vanessa Roldán; Vicente Vicente
Journal:  Haematologica       Date:  2010-06       Impact factor: 9.941

2.  Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique.

Authors:  Kirsten van Langevelde; Alexandr Srámek; Patrice W J Vincken; Jan-Kees van Rooden; Frits R Rosendaal; Suzanne C Cannegieter
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

Review 3.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

4.  Investigation on genetic thrombophilic factors in FFPE autopsy tissue from subjects who died from pulmonary embolism.

Authors:  Francesco Brandimarti; Federica Alessandrini; Mauro Pesaresi; Chiara Catalani; Letizia De Angelis; Roberta Galeazzi; Simona Giovagnetti; Rosaria Gesuita; Elisa Righi; Raffaele Giorgetti; Adriano Tagliabracci
Journal:  Int J Legal Med       Date:  2016-12-09       Impact factor: 2.686

5.  Association between congenital thrombophilia and outcomes in pulmonary embolism patients.

Authors:  Tian-Yu Lian; Dan Lu; Xin-Xin Yan; Jiang-Shan Tan; Fu-Hua Peng; Yong-Jian Zhu; Yun-Peng Wei; Tao Wu; Kai Sun; Xin Jiang; Lu Hua; Zhi-Cheng Jing
Journal:  Blood Adv       Date:  2020-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.